Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

3489results about How to "Inhibit aggregation" patented technology

Nanocrystal doped matrixes

The present invention provides matrixes doped with semiconductor nanocrystals. In certain embodiments, the semiconductor nanocrystals have a size and composition such that they absorb or emit light at particular wavelengths. The nanocrystals can comprise ligands that allow for mixing with various matrix materials, including polymers, such that a minimal portion of light is scattered by the matrixes. The matrixes of the present invention can also be utilized in refractive index matching applications. In other embodiments, semiconductor nanocrystals are embedded within matrixes to form a nanocrystal density gradient, thereby creating an effective refractive index gradient. The matrixes of the present invention can also be used as filters and antireflective coatings on optical devices and as down-converting layers. The present invention also provides processes for producing matrixes comprising semiconductor nanocrystals.
Owner:SAMSUNG ELECTRONICS CO LTD

Functionalized matrixes for dispersion of nanostructures

Matrixes doped with semiconductor nanocrystals are provided. In certain embodiments, the semiconductor nanocrystals have a size and composition such that they absorb or emit light at particular wavelengths. The nanocrystals can comprise ligands that allow for mixing with various matrix materials, including polymers, such that a minimal portion of light is scattered by the matrixes. The matrixes are optionally formed from the ligands. The matrixes of the present invention can also be utilized in refractive index matching applications. In other embodiments, semiconductor nanocrystals are embedded within matrixes to form a nanocrystal density gradient, thereby creating an effective refractive index gradient. The matrixes of the present invention can also be used as filters and antireflective coatings on optical devices and as down-converting layers. Processes for producing matrixes comprising semiconductor nanocrystals are also provided. Nanostructures having high quantum efficiency, small size, and / or a narrow size distribution are also described, as are methods of producing indium phosphide nanostructures and core-shell nanostructures with Group II-VI shells.
Owner:NANOSYS INC

Porous sintered metal-containing materials

InactiveUS20060211802A1Adversely affecting the physical and/or chemical stabilityInhibit aggregationAdditive manufacturingTransportation and packagingSolvent freeMetallic materials
A process for manufacturing a porous metal-containing material is provided. For example, a composition is provided comprising particles dispersed in at least one solvent, the particles comprising at least one polymer material and at least one metal-based compound. The solvent can be substantially removed from the composition, and the polymer material can be substantially decomposed, thereby converting the solvent-free particles into a porous metal-containing material. In addition, metal-containing materials produced in accordance with the above process and their use in implantable medical devices can be provided.
Owner:CINVENTION AG

Metal Nanoparticle, Metal Nanoparticle Colloid, Method for Storing Metal Nanoparticle Colloid, and Metal Coating Film

The object of the present invention is provide a metal nanoparticle which has a nano-sized average diameter while being highly stable as a particle, and a method for producing such metal nanoparticle. Particularly provides a metal nanoparticle having characteristics such as particle diameter and particle size distribution suitable for forming a conductive coating layer, and a method for producing such metal nanoparticle. The metal nanoparticle of the present invention is characterized in that it is obtained by reacting a reducing agent act on a solution containing an organic acid metal salt and an amine.
Owner:NIPPON SHOKUBAI CO LTD

Bioprocess for the generation of cells from spheroid-forming cells

The present inventors identified aggregation of embryonic stem cells and embryoid bodies (EBs) as the cause of the difficulty in generating large numbers of the embryonic stem cells (ES) cell-derived tissues. To counter this, the invention provides a novel bioprocess where aggregation of spheroid forming cells, such as embryonic stem cells and spheroids, such as EBs is controlled, such as by encapsulation of within a matrix. As a result, EBs can be generated with high efficiency and cultured in high cell density, well-mixed systems. Well-mixed conditions facilitate measurement and control of the bulk media conditions and allow for the use of scalable bioreactor systems for clinical production of tissue. Therefore, the invention enables generation of ES cell-derived tissue on a clinical scale. The invention is also applicable to any spheroid-forming cells and other types of pluripotent cells.
Owner:CARDION AG

Non-inclusion cyclodextrin complexes

InactiveUS20030109492A1Enhance cyclodextrin solubilizationImprove complexation efficiencyBiocideSugar derivativesWater solubleBULK ACTIVE INGREDIENT
The invention provides a number of methods for enhancing the aqueous solubility of an active ingredient which is insoluble or sparingly soluble in water. In one preferred embodiment, solubilization of the active ingredient is enhanced by combining it with beta-cyclodextrin in an aqueous complexation medium comprising beta-cyclodextrin and a negatively- or positively-charged compound which forms an inclusion or non-inclusion complex with beta-cyclodextrin and its inclusion complexes.
Owner:DECODE GENETICS EHF

Ultra-small LED electrode assembly and method for manufacturing same

Provided are a nano-scale LED assembly and a method for manufacturing the same. First, a nano-scale LED device that is independently manufactured may be aligned and connected to two electrodes different from each other to solve a limitation in which a nano-scale LED device having a nano unit is coupled to two electrodes different from each other in a stand-up state. Also, since the LED device and the electrodes are disposed on the same plane, light extraction efficiency of the LED device may be improved. Furthermore, the number of nano-scale LED devices may be adjusted. Second, since the nano-scale LED device does not stand up to be three-dimensionally coupled to upper and lower electrodes, but lies to be coupled to two electrodes different from each other on the same plane, the light extraction efficiency may be very improved. Also, since a separate layer is formed on a surface of the LED device to prevent the LED device and the electrode from being electrically short-circuited, defects of the LED electrode assembly may be minimized. Also, in preparation for the occurrence of the very rare defects of the LED device, the plurality of LED devices may be connected to the electrode to maintain the original function of the nano-scale LED electrode assembly.
Owner:SAMSUNG DISPLAY CO LTD

Back pressure adjustment apparatus for liquid ejection head

The back pressure adjustment apparatus for a liquid ejection head has: a container having a liquid accommodating chamber which is connected to the liquid ejection head and accommodates liquid to be supplied to the liquid ejection head, and a gas accommodating chamber which accommodates gas; a movable film which separates the liquid accommodating chamber and the gas accommodating chamber, and forms a portion of whole walls of the liquid accommodating chamber; and a pressure adjustment device which causes all or a portion of the movable film to deform so as to adjust pressure of the liquid accommodated in the liquid accommodating chamber.
Owner:FUJIFILM CORP

Hepatocyte growth factor for treatment of diabetes

The present invention provides a therapeutic agent for treatment of diabetes and hyperlipemia, especially a therapeutic agent for treatment of type II diabetes mellitus, which comprises as the active ingredient a neurotrophic factor such as BDNF (brain-derived neurotrophic factor), ligands of trkB or trkC receptors, NGF, NT-3, NT-4 / 5, CNTF, GDNF, HGF, etc. Different from conventional oral hypoglycemic agents being mainly used in the treatment of type II diabetes mellitus, the agent of the present invention exhibit blood lipid regulating effects and body fat accumulation regulating effects, in addition to the blood glucose regulating effects. Thus, the agent of the present invention are novel, and can reduce the risk factors in diabetes accompanied by hyperlipemia or obesity, without using any other agent.
Owner:SUMITOMO PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products